Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Show More...
-
Website https://amicusrx.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 5.45 EUR
-
Last Updated 29-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -1.98 -1.28 -1.07 -1.16 -0.93 -1.2 -1.49 -1.85 -1.88 -1.48 -1.27 Dividends USD Payout Ratio % * Shares Mil 28.0 35.0 46.0 51.0 74.0 110.0 134.0 153.0 186.0 240.0 251.0 Book Value Per Share * EUR 1.11 0.82 1.17 0.31 0.37 2.77 2.23 2.06 1.9 1.92 1.41 Free Cash Flow Per Share * EUR -1.4 -0.35 -0.8 -0.67 -0.56 -0.74 -1.18 -1.01 -1.55 -1.05 Return on Assets % -55.51 -48.71 -54.24 -50.19 -40.84 -23.63 -20.57 -34.14 -49.26 -43.46 -43.25 Financial Leverage (Average) 1.73 2.36 1.59 2.79 1.72 2.61 2.88 1.77 2.3 1.78 1.83 Return on Equity % -80.34 -93.97 -98.74 -103.74 -82.09 -56.22 -56.51 -79.66 -100.32 -86.99 -76.1 Return on Invested Capital % -76.69 -91.72 -97.17 -91.83 -68.81 -50.36 -43.4 -53.42 -57.05 -51.54 -50.32 Interest Coverage -214.67 -323.6 -583.61 -46.2 -82.72 -36.75 -25.05 -14.58 -17.86 -19.09 Current Ratio 6.76 3.46 11.32 8.44 7.66 2.94 3.06 5.6 6.4 4.04 4.45 Quick Ratio 6.62 3.15 11.07 7.91 7.51 2.91 2.98 5.25 6.11 3.77 4.14 Debt/Equity 0.02 0.31 0.08 0.12 0.43 0.47 0.94 0.43 0.5